Efficacy and Safety of Osimertinib for HK Chinese with Metastatic T790M Mutated NSCLC-real world setting.

Study identifier:D5160R00020

ClinicalTrials.gov identifier:NCT03219970

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An observational, non-interventional, multi-center, chart review study conducted among patients enrolled in an AZD9291 early access program in Hong Kong, with locally advanced/metastatic EGFR T790M mutation-positive NSCLC and prior exposure to EGFR TKI therapy.

Medical condition

Non-small Cell Lung Cancer

Phase

N/A

Healthy volunteers

No

Study drug

Osimertinib

Sex

All

Actual Enrollment

156

Study type

Observational

Age

18 Years - 100 Years

Date

Study Start Date: 05 Sept 2017
Primary Completion Date: 28 Oct 2020
Study Completion Date: 28 Oct 2020

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -

Verification:

Verified 01 Sept 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria